Education
About Us
Working with TipRanks
Follow Us
Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
ARTV Stock Chart & Stats
$3.31
$0.32(3.02%)
At close: 4:00 PM EST
$3.31
$0.32(3.02%)
Day’s Range― - ―
52-Week Range$1.47 - $13.19
Previous CloseN/A
Volume23.16K
Average Volume (3M)4.17M
Market Cap
$87.69M
Enterprise Value-$92.33M
Total Cash (Recent Filing)$122.97M
Total Debt (Recent Filing)$11.69M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Mar 30, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding24,425,762
10 Day Avg. Volume12,277,267
30 Day Avg. Volume4,166,063
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.32
Price to Sales (P/S)978.41
P/FCF Ratio-4.41
Enterprise Value/Market Cap-1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit139.47
Enterprise Value/Ebitda1.12
Forecast
1Y Price Target
$16.50Price Target Upside398.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentArtiva is engaging in proactive FDA discussions regarding a pivotal trial design in refractory rheumatoid arthritis, with feedback expected as soon as the first half of 2026.
Regulatory MilestoneAlloNK + anti-CD20 mAb, rituximab, has been granted FDA Fast Track Designation for the treatment of refractory rheumatoid arthritis, marking it as the first deep B cell depleter to receive this designation.
Safety ProfileArtiva presented impressive safety and B-cell depletion data that differentiates AlloNK from other cell therapies in autoimmune space and reinforced its potential in the community.
Bears Say
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $1.47 and its highest was $13.19 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $87.69M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Mar 30, 2026 which is in 124 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.868 by -$0.012.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.84.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,425,762 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.868. Following the earnings report the stock price went up 10.864%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.50 (398.49% Upside)
$16.50 (398.49% Upside)
Hedge Fund Trend
Decreased
By 283.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.97%
12-Months-Change
Fundamentals
Return on Equity
-47.96%
Trailing 12-Months
Asset Growth
123.14%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$16.50
▲(398.49% Upside)
Technical Analysis
Adicet Bio
―
ABVC BioPharma
―
Jasper Therapeutics
―
Pliant Therapeutics
―
Repare Therapeutics
―
Ownership Overview
6.88% Insiders
2.43% Mutual Funds
61.19% Other Institutional Investors
28.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---